Hepatitis C Virus Genotypes in the United States

Epidemiology, Pathogenicity, and Response to Interferon Therapy

Nizar N. Zein, Jorge Rakela, Edward L. Krawitt, K. Rajender Reddy, Tomonari Tominaga, David H. Persing

Research output: Contribution to journalArticle

323 Citations (Scopus)

Abstract

Objective: To study 1) the geographic distribution and clinical significance of hepatitis C virus (HCV) genotypes in the United States and 2) the influence of HCV genotypes on response to interferon therapy. Design: Hepatitis C virus genotype was determined in 179 stored serum samples obtained from patients who were positive for antibody to HCV and for HCV RNA by using polymerase chain reaction. Setting: Tertiary referral centers in four geographic regions of the United States. Patients: Patients who visited medical centers in the Midwest (50 patients), Northeast (42 patients), Southeast (35 patients), and West (52 patients). Measurements: Chaotropic lysis and isopropanol precipitation were used to extract RNA from serum. Polymerase chain reaction was done on the NS5 region and was followed by automated direct sequencing and genotyping of desalted amplification products. Results: 104 patients (58%) had subtype 1a; 38 (21%) had subtype 1b; 4 (2%) had subtype 2a; 23 (13%) had subtype 2b; 8 (5%) had subtype 3a; and 2 (1%) had subtype 4a. Examination of the known risk factors for acquiring HCV showed no association between genotype and mode of acquisition (blood transfusion, injection drug use, employment at a health care facility) or histologic findings at presentation (mild active hepatitis, moderately active hepatitis, or cirrhosis). Sixty-eight percent of patients with genotype 1a, 80% of patients with genotype 1b, and 37% of patients with genotype 2a or 2b had severe hepatitis. Thirteen of 46 (28%) patients with genotype 1a and 4 of 15 (26%) patients with genotype 1b had a complete biochemical response after 6 months of interferon therapy. In contrast, 10 of 14 (71%) patients with genotype 2a or 2b had a complete response to interferon therapy. Five of 39 (13%) patients with genotype 1a, 1 of 14 (7%) patients with genotype 1b, and 2 of 11 (18%) patients with genotype 2a or 2b had a sustained biochemical response. Conclusions: In the United States, HCV genotypes 1a and 1b are the predominant genotypes in patients with chronic hepatitis C. Genotype is not correlated with mode of virus acquisition or with histologic findings at presentation. Patients with HCV genotype 1a or 1b had more severe liver disease and lower rates of response to interferon therapy than did patients with HCV genotype 2a or 2b. These findings may have implications for predicting outcome and selecting patients for interferon treatment.

Original languageEnglish (US)
Pages (from-to)634-639
Number of pages6
JournalAnnals of Internal Medicine
Volume125
Issue number8
StatePublished - Oct 15 1996
Externally publishedYes

Fingerprint

Hepacivirus
Interferons
Virulence
Epidemiology
Genotype
Therapeutics
Hepatitis
Hospital Distribution Systems
Polymerase Chain Reaction
Hepatitis C Antibodies
2-Propanol
Health Facilities
Chronic Hepatitis C
DNA-Directed RNA Polymerases
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Zein, N. N., Rakela, J., Krawitt, E. L., Reddy, K. R., Tominaga, T., & Persing, D. H. (1996). Hepatitis C Virus Genotypes in the United States: Epidemiology, Pathogenicity, and Response to Interferon Therapy. Annals of Internal Medicine, 125(8), 634-639.

Hepatitis C Virus Genotypes in the United States : Epidemiology, Pathogenicity, and Response to Interferon Therapy. / Zein, Nizar N.; Rakela, Jorge; Krawitt, Edward L.; Reddy, K. Rajender; Tominaga, Tomonari; Persing, David H.

In: Annals of Internal Medicine, Vol. 125, No. 8, 15.10.1996, p. 634-639.

Research output: Contribution to journalArticle

Zein, NN, Rakela, J, Krawitt, EL, Reddy, KR, Tominaga, T & Persing, DH 1996, 'Hepatitis C Virus Genotypes in the United States: Epidemiology, Pathogenicity, and Response to Interferon Therapy', Annals of Internal Medicine, vol. 125, no. 8, pp. 634-639.
Zein, Nizar N. ; Rakela, Jorge ; Krawitt, Edward L. ; Reddy, K. Rajender ; Tominaga, Tomonari ; Persing, David H. / Hepatitis C Virus Genotypes in the United States : Epidemiology, Pathogenicity, and Response to Interferon Therapy. In: Annals of Internal Medicine. 1996 ; Vol. 125, No. 8. pp. 634-639.
@article{22c8eead7b224685aadc34a19821fce0,
title = "Hepatitis C Virus Genotypes in the United States: Epidemiology, Pathogenicity, and Response to Interferon Therapy",
abstract = "Objective: To study 1) the geographic distribution and clinical significance of hepatitis C virus (HCV) genotypes in the United States and 2) the influence of HCV genotypes on response to interferon therapy. Design: Hepatitis C virus genotype was determined in 179 stored serum samples obtained from patients who were positive for antibody to HCV and for HCV RNA by using polymerase chain reaction. Setting: Tertiary referral centers in four geographic regions of the United States. Patients: Patients who visited medical centers in the Midwest (50 patients), Northeast (42 patients), Southeast (35 patients), and West (52 patients). Measurements: Chaotropic lysis and isopropanol precipitation were used to extract RNA from serum. Polymerase chain reaction was done on the NS5 region and was followed by automated direct sequencing and genotyping of desalted amplification products. Results: 104 patients (58{\%}) had subtype 1a; 38 (21{\%}) had subtype 1b; 4 (2{\%}) had subtype 2a; 23 (13{\%}) had subtype 2b; 8 (5{\%}) had subtype 3a; and 2 (1{\%}) had subtype 4a. Examination of the known risk factors for acquiring HCV showed no association between genotype and mode of acquisition (blood transfusion, injection drug use, employment at a health care facility) or histologic findings at presentation (mild active hepatitis, moderately active hepatitis, or cirrhosis). Sixty-eight percent of patients with genotype 1a, 80{\%} of patients with genotype 1b, and 37{\%} of patients with genotype 2a or 2b had severe hepatitis. Thirteen of 46 (28{\%}) patients with genotype 1a and 4 of 15 (26{\%}) patients with genotype 1b had a complete biochemical response after 6 months of interferon therapy. In contrast, 10 of 14 (71{\%}) patients with genotype 2a or 2b had a complete response to interferon therapy. Five of 39 (13{\%}) patients with genotype 1a, 1 of 14 (7{\%}) patients with genotype 1b, and 2 of 11 (18{\%}) patients with genotype 2a or 2b had a sustained biochemical response. Conclusions: In the United States, HCV genotypes 1a and 1b are the predominant genotypes in patients with chronic hepatitis C. Genotype is not correlated with mode of virus acquisition or with histologic findings at presentation. Patients with HCV genotype 1a or 1b had more severe liver disease and lower rates of response to interferon therapy than did patients with HCV genotype 2a or 2b. These findings may have implications for predicting outcome and selecting patients for interferon treatment.",
author = "Zein, {Nizar N.} and Jorge Rakela and Krawitt, {Edward L.} and Reddy, {K. Rajender} and Tomonari Tominaga and Persing, {David H.}",
year = "1996",
month = "10",
day = "15",
language = "English (US)",
volume = "125",
pages = "634--639",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "8",

}

TY - JOUR

T1 - Hepatitis C Virus Genotypes in the United States

T2 - Epidemiology, Pathogenicity, and Response to Interferon Therapy

AU - Zein, Nizar N.

AU - Rakela, Jorge

AU - Krawitt, Edward L.

AU - Reddy, K. Rajender

AU - Tominaga, Tomonari

AU - Persing, David H.

PY - 1996/10/15

Y1 - 1996/10/15

N2 - Objective: To study 1) the geographic distribution and clinical significance of hepatitis C virus (HCV) genotypes in the United States and 2) the influence of HCV genotypes on response to interferon therapy. Design: Hepatitis C virus genotype was determined in 179 stored serum samples obtained from patients who were positive for antibody to HCV and for HCV RNA by using polymerase chain reaction. Setting: Tertiary referral centers in four geographic regions of the United States. Patients: Patients who visited medical centers in the Midwest (50 patients), Northeast (42 patients), Southeast (35 patients), and West (52 patients). Measurements: Chaotropic lysis and isopropanol precipitation were used to extract RNA from serum. Polymerase chain reaction was done on the NS5 region and was followed by automated direct sequencing and genotyping of desalted amplification products. Results: 104 patients (58%) had subtype 1a; 38 (21%) had subtype 1b; 4 (2%) had subtype 2a; 23 (13%) had subtype 2b; 8 (5%) had subtype 3a; and 2 (1%) had subtype 4a. Examination of the known risk factors for acquiring HCV showed no association between genotype and mode of acquisition (blood transfusion, injection drug use, employment at a health care facility) or histologic findings at presentation (mild active hepatitis, moderately active hepatitis, or cirrhosis). Sixty-eight percent of patients with genotype 1a, 80% of patients with genotype 1b, and 37% of patients with genotype 2a or 2b had severe hepatitis. Thirteen of 46 (28%) patients with genotype 1a and 4 of 15 (26%) patients with genotype 1b had a complete biochemical response after 6 months of interferon therapy. In contrast, 10 of 14 (71%) patients with genotype 2a or 2b had a complete response to interferon therapy. Five of 39 (13%) patients with genotype 1a, 1 of 14 (7%) patients with genotype 1b, and 2 of 11 (18%) patients with genotype 2a or 2b had a sustained biochemical response. Conclusions: In the United States, HCV genotypes 1a and 1b are the predominant genotypes in patients with chronic hepatitis C. Genotype is not correlated with mode of virus acquisition or with histologic findings at presentation. Patients with HCV genotype 1a or 1b had more severe liver disease and lower rates of response to interferon therapy than did patients with HCV genotype 2a or 2b. These findings may have implications for predicting outcome and selecting patients for interferon treatment.

AB - Objective: To study 1) the geographic distribution and clinical significance of hepatitis C virus (HCV) genotypes in the United States and 2) the influence of HCV genotypes on response to interferon therapy. Design: Hepatitis C virus genotype was determined in 179 stored serum samples obtained from patients who were positive for antibody to HCV and for HCV RNA by using polymerase chain reaction. Setting: Tertiary referral centers in four geographic regions of the United States. Patients: Patients who visited medical centers in the Midwest (50 patients), Northeast (42 patients), Southeast (35 patients), and West (52 patients). Measurements: Chaotropic lysis and isopropanol precipitation were used to extract RNA from serum. Polymerase chain reaction was done on the NS5 region and was followed by automated direct sequencing and genotyping of desalted amplification products. Results: 104 patients (58%) had subtype 1a; 38 (21%) had subtype 1b; 4 (2%) had subtype 2a; 23 (13%) had subtype 2b; 8 (5%) had subtype 3a; and 2 (1%) had subtype 4a. Examination of the known risk factors for acquiring HCV showed no association between genotype and mode of acquisition (blood transfusion, injection drug use, employment at a health care facility) or histologic findings at presentation (mild active hepatitis, moderately active hepatitis, or cirrhosis). Sixty-eight percent of patients with genotype 1a, 80% of patients with genotype 1b, and 37% of patients with genotype 2a or 2b had severe hepatitis. Thirteen of 46 (28%) patients with genotype 1a and 4 of 15 (26%) patients with genotype 1b had a complete biochemical response after 6 months of interferon therapy. In contrast, 10 of 14 (71%) patients with genotype 2a or 2b had a complete response to interferon therapy. Five of 39 (13%) patients with genotype 1a, 1 of 14 (7%) patients with genotype 1b, and 2 of 11 (18%) patients with genotype 2a or 2b had a sustained biochemical response. Conclusions: In the United States, HCV genotypes 1a and 1b are the predominant genotypes in patients with chronic hepatitis C. Genotype is not correlated with mode of virus acquisition or with histologic findings at presentation. Patients with HCV genotype 1a or 1b had more severe liver disease and lower rates of response to interferon therapy than did patients with HCV genotype 2a or 2b. These findings may have implications for predicting outcome and selecting patients for interferon treatment.

UR - http://www.scopus.com/inward/record.url?scp=0030587906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030587906&partnerID=8YFLogxK

M3 - Article

VL - 125

SP - 634

EP - 639

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 8

ER -